Sequoia Financial Advisors LLC Has $3.92 Million Stock Holdings in Stryker Corporation $SYK

Sequoia Financial Advisors LLC trimmed its holdings in Stryker Corporation (NYSE:SYK) by 14.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,466 shares of the medical technology company’s stock after selling 2,037 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Stryker were worth $3,925,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Amundi lifted its stake in shares of Stryker by 18.3% during the second quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock valued at $392,402,000 after acquiring an additional 192,447 shares during the period. Veritas Asset Management LLP bought a new position in Stryker in the second quarter valued at about $168,057,000. Rakuten Investment Management Inc. acquired a new stake in Stryker in the second quarter worth about $18,646,000. Royal Bank of Canada increased its position in Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the period. Finally, Rathbones Group PLC raised its holdings in Stryker by 647.9% during the 4th quarter. Rathbones Group PLC now owns 219,265 shares of the medical technology company’s stock worth $77,065,000 after purchasing an additional 189,948 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, insider Dylan Crotty sold 441 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SYK. Evercore set a $350.00 target price on shares of Stryker in a research report on Monday, July 6th. Wells Fargo & Company lowered their price target on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research report on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. UBS Group began coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective on the stock. Finally, Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Eighteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $380.40.

Stryker Price Performance

Shares of SYK opened at $275.28 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $392.55. The stock has a market cap of $105.59 billion, a P/E ratio of 28.53, a price-to-earnings-growth ratio of 1.73 and a beta of 0.76. The stock’s 50-day moving average price is $324.62 and its two-hundred day moving average price is $326.48.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.3%. Stryker’s payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.